NCT02119884View on ClinicalTrials.gov

Hemodynamic Effects of Terlipressin and High Dose Octreotide

PHASE4CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Gastric and Esophageal Varices
Interventions
DRUG

Terlipressin

Patients in the terlipressin group receive a single IV injection of 2 mg of terlipressin and a continuous IV infusion of normal saline.

DRUG

Octreotide

Patients in high dose octreotide receive a single injection of 100μg octreotide and continuous IV infusion of 50 μg/h of octreotide.

Trial Locations (1)

200032

180 Fenglin Road, Shanghai

All Listed Sponsors
collaborator

Shandong Provincial Hospital

OTHER_GOV

lead

Shanghai Zhongshan Hospital

OTHER

NCT02119884 - Hemodynamic Effects of Terlipressin and High Dose Octreotide | Biotech Hunter | Biotech Hunter